MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients

March 9, 2022 – IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable for patients, announces today that it has received Clinical Trial Application approval from the British Medicines & Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I/II clinical …

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients Read More »